Monthly PubMed Review

Monthly PubMed Review of the Most relevant research on Lung Cancer

January 2020


Long noncoding RNA VPS9D1-AS1 augments the malignant phenotype of non-small cell lung cancer by sponging microRNA-532-3p and thereby enhancing HMGA2 expression. Han X1, Huang T1, Han J2. Aging (Albany NY). 2020 Jan 5;12(1):370-386. doi: 10.18632/aging.102628. Epub 2020 Jan 5.

Comprehensive Analysis of Aberrantly Expressed Profiles of lncRNAs and miRNAs with Associated ceRNA Network in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma. Dong R1, Liu J2, Sun W2, Ping W3. Pathol Oncol Res. 2020 Jan 2. doi: 10.1007/s12253-019-00780-4. [Epub ahead of print]

Knockdown of circ-ABCB10 promotes sensitivity of lung cancer cells to cisplatin via miR-556-3p/AK4 axis. Wu Z1, Gong Q2, Yu Y2, Zhu J2, Li W3. BMC Pulm Med. 2020 Jan 13;20(1):10. doi: 10.1186/s12890-019-1035-z.


Education Level Predicts Appropriate Follow-Up of Incidental Findings From Lung Cancer Screening. Kapoor S1, Deppen SA2, Paulson AB3, Haddad D4, Cook JP3, Sandler KL3. J Am Coll Radiol. 2020 Jan 10. pii: S1546-1440(19)31477-2. doi: 10.1016/j.jacr.2019.12.014. [Epub ahead of print]

MicroRNA-based biomarkers for diagnosis of non-small cell lung cancer (NSCLC). Liao J1, Shen J1, Leng Q1, Qin M1, Zhan M2, Jiang F1. Thorac Cancer. 2020 Jan 28. doi: 10.1111/1759-7714.13337. [Epub ahead of print]

Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes. Tian P1,2, Liu Y1, Zeng H1, Tang Y3, Lizaso A4, Ye J4, Shao L4, Li Y5. J Cancer Res Clin Oncol. 2020 Jan 1. doi: 10.1007/s00432-019-03116-6. [Epub ahead of print]

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. Ruiz-Cordero R1, Ma J2, Khanna A3, et al. BMC Cancer. 2020 Jan 31;20(1):83. doi: 10.1186/s12885-020-6579-z.

Patient-centered Radiology Reporting for Lung Cancer Screening. Vitzthum von Eckstaedt H 5th1, Kitts AB2, Swanson C1, Hanley M1, Krishnaraj A1. J Thorac Imaging. 2020 Jan 6. doi: 10.1097/RTI.0000000000000469. [Epub ahead of print]

Screening Mammography Visits as Opportunities to Engage Smokers With Tobacco Cessation Services and Lung Cancer Screening. Wang GX1, Narayan AK2, Park ER3, Lehman CD2, Gorenstein JT4, Flores EJ2. Am Coll Radiol. 2020 Jan 10. pii: S1546-1440(19)31450-4. doi: 10.1016/j.jacr.2019.12.008. [Epub ahead of print]

Development of Decisional Values Statements for Lung Cancer Screening Among African American Smokers. Williams RM1, Beck KH2, Butler J 3rd2, Lee S2, Wang MQ2, Taylor KL3, Knott CL2. J Cancer Educ. 2020 Jan 9. doi: 10.1007/s13187-020-01687-4. [Epub ahead of print]

Effect of a Patient Decision Aid on Lung Cancer Screening Decision-Making by Persons Who Smoke: A Randomized Clinical Trial. Volk RJ1, Lowenstein LM1, Leal VB1, et al. JAMA Netw Open. 2020 Jan 3;3(1):e1920362. doi: 10.1001/jamanetworkopen.2019.20362.


The association of robotic lobectomy volume and nodal upstaging in non-small cell lung cancer. Okusanya OT1, Lutfi W2, Baker N2, et al. J Robot Surg. 2020 Jan 16. doi: 10.1007/s11701-020-01044-z. [Epub ahead of print]

Feasibility and effectiveness of thoracoscopic pulmonary segmentectomy for non-small cell lung cancer. Ma M1, He F1, Lv X1, Wang X2, Dong S1, Liu C1, Zhou C1. Medicine (Baltimore). 2020 Jan;99(5):e18959. doi: 10.1097/MD.0000000000018959.

A prospective study examining the impact of uniportal video-assisted thoracic surgery on the short-term quality of life in patients with lung cancer. Xu GW1, Xie MR1, Wu HR1, Xiong R1, Li CW1, Xu SB1, Xu MQ1, Li T1. Thorac Cancer. 2020 Jan 22. doi: 10.1111/1759-7714.13305. [Epub ahead of print]


Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy. Weiss JM1, Pennell N2, Deal AM1, et al. Cancer. 2020 Jan 14. doi: 10.1002/cncr.32573. [Epub ahead of print]

Lung Stereotactic Body Radiotherapy and Concurrent Immunotherapy: A Multi-Center Safety and Toxicity Analysis. Tian S1, Switchenko JM2, Buchwald ZS1, et al. Int J Radiat Oncol Biol Phys. 2020 Jan 23. pii: S0360-3016(19)34548-1. doi: 10.1016/j.ijrobp.2019.12.030. [Epub ahead of print]

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. Schoenfeld AJ1, Chan JM1, Kubota D2, et al. Clin Cancer Res. 2020 Jan 7. pii: clincanres.3563.2019. doi: 10.1158/1078-0432.CCR-19-3563. [Epub ahead of print]

Cost-effectiveness of pembrolizumab for advanced non-small cell lung cancer patients with varying comorbidity burden. Criss SD1, Palazzo L1, Watson TR1, Paquette AM1, Sigel K2, Wisnivesky J2,3, Kong CY1,4.

The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of life. Park R1, Shaw JW2, Korn A3, McAuliffe J3. J Cancer Surviv. 2020 Jan 16. doi: 10.1007/s11764-020-00853-3. [Epub ahead of print]

Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis. Mo J1, Hu X2, Gu L3, Chen B4, Khadaroo PA5, Shen Z1, Dong L6, Lv Y1, Chitumba MN7, Liu J8. V

Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era. Kehl KL1, Hassett MJ1, Schrag D1. Cancer Med. 2020 Jan 27. doi: 10.1002/cam4.2854. [Epub ahead of print]

Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589). Zhang H1,2, Qian G2, Zong D2, Fan S1, Owonikoko TK2, Ramalingam SS2, Sun SY2. Cancer. 2020 Jan 30. doi: 10.1002/cncr.32744. [Epub ahead of print]

Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase 2 KEYNOTE-158 Study. Strosberg JR1, Mizuno N2, Doi T3, et al. Clin Cancer Res. 2020 Jan 24. pii: clincanres.3014.2019. doi: 10.1158/1078-0432.CCR-19-3014. [Epub ahead of print]

Measuring Tumor Mutational Burden Using Whole-Exome Sequencing. Vilimas T1. Methods Mol Biol. 2020;2055:63-91. doi: 10.1007/978-1-4939-9773-2_3.

Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab. Ksienski D1, Wai ES2, Croteau NS3, et al. J Geriatr Oncol. 2020 Jan 11. pii: S1879-4068(19)30406-0. doi: 10.1016/j.jgo.2020.01.006. [Epub ahead of print]

Imaging of Novel Oncologic Treatments in Lung Cancer Part 1: Systemic Therapies. Halpenny D1, O’Dwyer E, Girshman J, Ginsberg MS. J Thorac Imaging. 2020 Jan;35(1):26-36. doi: 10.1097/RTI.0000000000000451.

A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers. Paik PK1, Kim RK2, Ahn L3, et al. Clin Cancer Res. 2020 Jan 9. pii: clincanres.3060.2019. doi: 10.1158/1078-0432.CCR-19-3060. [Epub ahead of print]


Impact of contouring variability on oncological PET radiomics features in the lung. Yang F1, Simpson G2, Young L3, Ford J4, Dogan N4, Wang L4. Sci Rep. 2020 Jan 15;10(1):369. doi: 10.1038/s41598-019-57171-7.

CT Densitometry and Morphology of Radiofrequency-Ablated Stage IA Non-Small Cell Lung Cancer: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) Trial. Alexander ES1, Xiong L2, Baird GL3, Fernando H4, Dupuy DE5. J Vasc Interv Radiol. 2020 Feb;31(2):286-293. doi: 10.1016/j.jvir.2019.09.010. Epub 2020 Jan 3.

Predictors of Distant Recurrence Following Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer. Wong JK1, Shaikh T1, DeMora L2, Zhang E1, Borghaei H3, Hayes SB1, Kumar S1, Meyer JE1, Hallman MA1. Am J Clin Oncol. 2020 Jan 7. doi: 10.1097/COC.0000000000000662. [Epub ahead of print]

Evaluating Positron Emission Tomography-Based Functional Imaging Changes in the Heart After Chemo-Radiation for Patients With Lung Cancer. Vinogradskiy Y1, Diot Q2, Jones B2, et al. Int J Radiat Oncol Biol Phys. 2020 Jan 23. pii: S0360-3016(19)34526-2. doi: 10.1016/j.ijrobp.2019.12.013. [Epub ahead of print]

Impact of Patient Stage and Disease Characteristics on the proposed Radiation Oncology Alternative Payment Model (RO-APM) at a Large Academic Cancer Center. Waddle MR1, Stross WC1, Vallow LA1, et al. Int J Radiat Oncol Biol Phys. 2020 Jan 27. pii: S0360-3016(19)34525-0. doi: 10.1016/j.ijrobp.2019.12.012. [Epub ahead of print]

Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials. Chen D#1, Menon H#2, Verma V3, et al. J Immunother Cancer. 2020 Jan;8(1). pii: e000492. doi: 10.1136/jitc-2019-000492.


The impact of quantitative CT-based tumor volumetric features on the outcomes of patients with limited stage small cell lung cancer. Kamran SC1,2, Coroller T3,4, Milani N4, et al. Radiat Oncol. 2020 Jan 14;15(1):14. doi: 10.1186/s13014-020-1460-4.

A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled Trials. Wu Q1,2, Xiong Y1,2, Zhang S2,3, Chen X2,3, Yi F3, Wei Y1, Zhang W1. Front Oncol. 2020 Jan 8;9:1460. doi: 10.3389/fonc.2019.01460. eCollection 2019.

Nivolumab for the treatment of small cell lung cancer. Simeone E1, Grimaldi AM1, Festino L1, Trojaniello C1, Vitale MG1, Vanella V1, Curvietto M1, Ascierto PA1. Expert Rev Respir Med. 2020 Jan;14(1):5-13. doi: 10.1080/17476348.2020.1681977. Epub 2019 Oct 29.


Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial. Noronha V1, Bhattacharjee A2, Patil VM1, et al. Chest. 2020 Jan 17. pii: S0012-3692(20)30032-5. doi: 10.1016/j.chest.2019.11.048. [Epub ahead of print]

Determining the prevalence and severity of cancer cachexia in advanced non-small cell lung cancer and its relationship with chemotherapy outcomes. White R1,2, Weekes CE3, Grant R4, Baldwin C5, Ahmed H4. Support Care Cancer. 2020 Jan 8. doi: 10.1007/s00520-019-05259-1. [Epub ahead of print]

A cross sectional study to determine the prevalence of cough and its impact in patients with lung cancer: a patient unmet need. Harle A1,2, Molassiotis A3, Buffin O4,5, Burnham J4,6, Smith J7,8, Yorke J4,9, Blackhall FH10,11. BMC Cancer. 2020 Jan 6;20(1):9. doi: 10.1186/s12885-019-6451-1.

Preoperative Anxiety and Intraoperative Nociception in Patients Undergoing Thoracic Surgery. Takenaka S1, Hirose M2. J Surg Res. 2020 Jan 6;249:13-17. doi: 10.1016/j.jss.2019.12.017. [Epub ahead of print]

The association of physical function and quality of life on physical activity for non-small cell lung cancer survivors. Yoo JS1,2, Yang HC3, Lee JM3, Kim MS3, Park EC4, Chung SH5. Support Care Cancer. 2020 Jan 25. doi: 10.1007/s00520-020-05302-6. [Epub ahead of print]


Efficacy and safety of Jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial. Xiao Z1, Hu L2, Lin J1, Lu L3, Huang X1, Zhu X4, Teo C5, Lin L6. Trials. 2020 Jan 16;21(1):94. doi: 10.1186/s13063-019-3982-3.

Recent advances in natural therapeutic approaches for the treatment of cancer. Wang XJ1, Chen JY2, Fu LQ1, Yan MJ3. J Chemother. 2020 Jan 13:1-13. doi: 10.1080/1120009X.2019.1707417. [Epub ahead of print]

Potential of Thai Herbal Extracts on Lung Cancer Treatment by Inducing Apoptosis and Synergizing Chemotherapy. Poofery J1, Khaw-On P1, Subhawa S1, et al. Molecules. 2020 Jan 6;25(1). pii: E231. doi: 10.3390/molecules25010231.


Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice. Mitchell AP1,2,3, Kinlaw AC3,4, Peacock-Hinton S5, Dusetzina SB6,7, Sanoff HK2,8, Lund JL5,8. Oncologist. 2020 Jan;25(1):46-54. doi: 10.1634/theoncologist.2019-0338. Epub 2019 Oct 14.

Network-Based Matching of Patients and Targeted Therapies for Precision Oncology. Liu Q1, Ha MJ, Bhattacharyya R, Garmire L, Baladandayuthapani V. Pac Symp Biocomput. 2020;25:623-634.

 A Smartphone App Designed to Help Cancer Patients Stop Smoking: Results From a Pilot Randomized Trial on Feasibility, Acceptability, and Effectiveness. Bricker JB1,2, Watson NL1, Heffner JL1, Sullivan B1, Mull K1, Kwon D1,2, Westmaas JL3, Ostroff J4. JMIR Form Res. 2020 Jan 17;4(1):e16652. doi: 10.2196/16652.

Follow-Up of the Libby, Montana Screening Cohort: A 17-Year Mortality Study. Larson TC1, Williamson L, Antao VC. J Occup Environ Med. 2020 Jan;62(1):e1-e6. doi: 10.1097/JOM.0000000000001760.

Improving Clinical Trial Participant Prescreening With Artificial Intelligence (AI): A Comparison of the Results of AI-Assisted vs Standard Methods in 3 Oncology Trials. Calaprice-Whitty D1, Galil K2, Salloum W2, Zariv A2, Jimenez B2. Ther Innov Regul Sci. 2020 Jan;54(1):69-74. doi: 10.1007/s43441-019-00030-4. Epub 2020 Jan 6.

COPD and lung cancer incidence in the Women’s Health Initiative Observational Study: A brief report. Nagasaka M1, Lehman A2, Chlebowski R3, et al. Lung Cancer. 2020 Jan 7;141:78-81. doi: 10.1016/j.lungcan.2020.01.006. [Epub ahead of print]

Lung Cancer Stigma: Does Smoking History Matter? Williamson TJ1, Kwon DM1, Riley KE2, Shen MJ3, Hamann HA4,5, Ostroff JS1. Ann Behav Med. 2020 Jan 14. pii: kaz063. doi: 10.1093/abm/kaz063. [Epub ahead of print]

Financial toxicity in lung cancer: an assessment of magnitude, perception, and impact on quality of life. Hazell SZ1, Fu W2, et al. Ann Oncol. 2020 Jan;31(1):96-102. doi: 10.1016/j.annonc.2019.10.006.

Mortality in a cohort of US firefighters from San Francisco, Chicago and Philadelphia: an update. Pinkerton L1, Bertke SJ1, Yiin J2, Dahm M1, Kubale T3, Hales T4, Purdue M5, Beaumont JJ6, Daniels R7. Occup Environ Med. 2020 Feb;77(2):84-93. doi: 10.1136/oemed-2019-105962. Epub 2020 Jan 2.

Association of Physician Peer Influence With Subsequent Physician Adoption and Use of Bevacizumab. Keating NL1,2, O’Malley AJ3, Onnela JP4, Gray SW5, Landon BE1,6. JAMA Netw Open. 2020 Jan 3;3(1):e1918586. doi: 10.1001/jamanetworkopen.2019.18586.